Latest News

Artiva prepares to kick off Phase I/II trial for NK cell therapy

Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in…

IRLAB dosing patients in Phase IIb Parkinson’s disease trial

Swedish company IRLAB Therapeutics is dosing patients in its ongoing Phase IIb trial of its pipeline candidate pirepemat in Parkinson’s disease…

Notable Labs hopes for success with Boehringer’s failed AML drug

California-based Notable Labs is hoping for success as it launches a Phase II trial of Boehringer Ingelheim’s failed candidate volasertib…

Mediwound optimistic about wound therapy EscharEx after Phase II VLU trial

Israel-based MediWound has announced positive results from a head-to-head comparison of its wound treatment EscharEx versus standard of care (SoC)…

Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop

Oramed Pharmaceuticals has announced it is looking to reinitiate a Phase III trial of its oral insulin candidate in type…

New data supports development of Teva and Sanofi’s anti-TL1A IBD therapy

Teva Pharmaceuticals and Sanofi have revealed new data that further bolsters their $1.5bn co-development deal of an anti-tumour necrosis factor-like…

SCOPE: Changing protocol language and site actions are key to making trials inclusive

Changing the language used in trial protocols and continually conversing with sites are some ways by which trialists can make…

SCOPE: FDA facilitates AI and ML use for clinical trials and drug development

The US Food and Drug Administration (FDA) is focusing on how artificial intelligence (AI) can be used to support clinical…

SCOPE: AI in clinical trials is here to stay. How should it be used?

Artificial intelligence (AI) is a great assistance for clinical trials but its use should still be approached with some caution,…

Pharma and biotech concerned about the stability of large CROs, survey finds

Pharma and biotechs have shared concerns about working with large CROs, saying that the ‘one-stop shop’ model is no longer…